BridgeBio Pharma, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BBIO, updated each market day.
BBIO AI Sentiment
AI predicts BridgeBio Pharma, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About BridgeBio Pharma, Inc. Common Stock
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Sector
Exchange
Market Cap
$13,894,151,964
Cap Tier
Employees
839
Headquarters
PALO ALTO, CA
Listed Since
June 27, 2019
Website
BBIO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BBIO Volatility
BridgeBio Pharma, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
